Eli Lilly Stock Gains After FDA Advisors Recommend Alzheimer's Drug Donanemab

Key TakeawaysEli Lilly shares rose in extended-hours trading on Monday after a panel of independent advisors unanimously recommended the pharmaceutical giant’s Alzheimer’s drug donanemab, paving the way for its approval later this year.If approved, the drug would join Leqembi, a similar Alzhiemer’s drug manufactured by Biogen and its Japanese partner Eisai, to expand treatment options for the 6 million Americans who live with the disease.Monitor the $795 level during periods of profit taking, an area on the ...